NDAORALTABLET
Approved
Apr 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDROMOX (quinethazone) is an oral thiazide-type diuretic approved in 1963 for hypertension and edema management. The drug works by inhibiting sodium and chloride reabsorption in the distal convoluted tubule, reducing fluid volume and blood pressure. It represents a legacy small-molecule therapeutic in a crowded antihypertensive market.
LOE Approaching
As LOE approaches, commercial teams are likely consolidating resources; expect stabilization or wind-down activities rather than expansion hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYDROMOX offers minimal career growth prospects as it enters LOE with zero linked job openings. Working on this product involves legacy brand management, generic defense, and payer negotiations rather than launch or innovation work. Career value lies primarily in contract negotiation, managed care expertise, and operational efficiency—not in market expansion or clinical advancement.
Brand Manager
Worked on HYDROMOX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.